content_image/132608.jpg content_image/132609.jpg
## Selected Financial Data 

The selected financial data presented below summarizes certain financial data which has been derived from and should be read in conjunction with our consolidated financial statements and footnotes thereto included elsewhere herein. See also Management’s Discussion and Analysis of Financial Condition and Results of Operations. 

<img src='content_image/132608.jpg'>

(1) Revenues for 1997 include $17.4 million from fees related to the sublicense of iloperidone to Novartis. Revenues for 2001 include $2.5 million license fee payment from Novartis for the development and commercialization of iloperidone in Japan. 

(2) Acquired in-process research and development reflects the acquisition of GeoMed in 2000, the acquisition of a minority interest in Theracell in 1999, and the acquisition of an exclusive worldwide (except for Japan) license for iloperidone in 1997. 

(3) Other income for 1997 includes a gain of $8.4 million from the sale of a research technology. 

<img src='content_image/132609.jpg'>

